diclofenac has been researched along with vinpocetine in 4 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (50.00) | 24.3611 |
| 2020's | 2 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bellman, K; Knegtel, RM; Settimo, L | 1 |
| Borghi, SM; Bussmann, AJC; Casagrande, R; Coelho-Silva, L; Crespigio, J; Fattori, V; Giroldo, AC; Guazelli, CFS; Ludwig, NG; Mazzuco, TL; Verri, WA | 1 |
| Abdel-Razek, NS; Salem, HA; Wadie, W | 1 |
| Butakova, JS; Parshin, MS; Samartsev, IN; Zhivolupov, SA | 1 |
4 other study(ies) available for diclofenac and vinpocetine
| Article | Year |
|---|---|
Comparison of the accuracy of experimental and predicted pKa values of basic and acidic compounds.
Topics: Chemistry, Pharmaceutical; Forecasting; Hydrogen-Ion Concentration; Pharmaceutical Preparations; Random Allocation | 2014 |
Vinpocetine reduces diclofenac-induced acute kidney injury through inhibition of oxidative stress, apoptosis, cytokine production, and NF-κB activation in mice.
Topics: Acute Kidney Injury; Animals; Anti-Inflammatory Agents, Non-Steroidal; Apoptosis; Cytokines; Diclofenac; Kidney; Male; Mice; NF-kappa B; Nootropic Agents; Oxidative Stress; Protective Agents; Vinca Alkaloids | 2017 |
Phosphodiesterase (1, 3 & 5) inhibitors attenuate diclofenac-induced acute kidney toxicity in rats.
Topics: Acute Kidney Injury; Animals; Blood Urea Nitrogen; Cilostazol; Creatinine; Diclofenac; Kidney; Male; NF-kappa B; Pentoxifylline; Phosphodiesterase Inhibitors; Phosphoric Diester Hydrolases; Rats; Rats, Wistar; Sildenafil Citrate; Toll-Like Receptor 4; Tumor Necrosis Factor-alpha; Vinca Alkaloids | 2021 |
[The open observational study of aceclofenac and vinpocetine effectiveness and tolerability in treatment of patients with chronic cerebrovascular disease after COVID-19 (AQUA study)].
Topics: Aged; Cerebrovascular Disorders; COVID-19; COVID-19 Drug Treatment; Diclofenac; Female; Humans; Male; Middle Aged; Post-Acute COVID-19 Syndrome; Vinca Alkaloids | 2021 |